Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...

The FDA approved the use of pembrolizumab (Keytruda; Merck) and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for use in patients 12 years and older with solid tumor indications approved for the ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

While administering monoclonal antibodies via intravenous infusion is standard practice to prevent severe hospitalization and death in outpatients with COVID-19, new research from UPMC shows giving ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...